Austin, Texas — According to state and local economic development sources Molecular Templates plans to invest $795,000.00 to build out 15,500 square feet of new space in Austin. The company plans to occupy the new space at 9301 Amberglen Blvd Suite 100 in Austin, on or about January 1, 2021. According to the company website Molecular Templates (MTEM) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary Engineered Toxin Body (ETB) platform. MTEM’s first immunotoxin, MT-3724, is in clinical development for non-Hodgkin’s lymphoma. Pipeline products for additional oncology targets are being advanced toward clinical development.

To learn more about Molecular Templates, visit http://mtem.com/

Company Contact:
Eric Poma, Chief Executive Officer
eric.poma@mtem.com
512-233-2709

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved